Cribstone Capital Management LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 88.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,009 shares of the biopharmaceutical company’s stock after selling 15,302 shares during the period. Cribstone Capital Management LLC’s holdings in Gilead Sciences were worth $142,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of GILD. Hall Laurie J Trustee raised its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the period. Cable Hill Partners LLC boosted its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. boosted its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Finally, Penserra Capital Management LLC boosted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 74.05% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at 75.94 on Friday. The firm has a market cap of $99.18 billion, a P/E ratio of 8.25 and a beta of 1.21. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10. The company has a 50-day moving average of $69.98 and a 200-day moving average of $68.63. Gilead Sciences also saw unusually large options trading activity on Wednesday. Investors bought 23,892 put options on the stock. This represents an increase of approximately 241% compared to the average volume of 7,005 put options.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period last year, the business posted $3.08 EPS. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences, Inc. will post $8.72 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/07/29/cribstone-capital-management-llc-has-142000-position-in-gilead-sciences-inc-gild.html.
A number of research analysts have commented on GILD shares. Zacks Investment Research upgraded Gilead Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 11th. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Jefferies Group LLC reiterated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, April 6th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $79.00 price objective on shares of Gilead Sciences in a research note on Friday, May 5th. Thirteen equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $80.33.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Over the last three months, insiders sold 128,276 shares of company stock valued at $9,190,610. Insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
